Stockreport

AbCellera Biologics Pivots to Internal Pipeline at JPMorgan, Teases Key Milestones for 2026 [Yahoo! Finance]

AbCellera Biologics Inc. - Common Shares  (ABCL) 
PDF prioritize company-owned assets with several near-term development milestones planned. The lead program, AbCell 635 , is a first-in-class NK3R antibody for menopausal [Read more]